Literature DB >> 16809927

Regulating of growth hormone sensitivity by sex steroids: implications for therapy.

Ken K Y Ho1, James Gibney, Gudmundur Johannsson, Troels Wolthers.   

Abstract

Growth hormone (GH) is an important regulator of body composition, reducing body fat by stimulating fat oxidation and enhancing lean body mass by stimulating protein accretion. The emergence of differences in body composition between the sexes during puberty suggests sex steroids modulate the action of GH. Work from our laboratory have investigated the influence of estrogens and androgens on the metabolic actions of GH in human adults. The liver is an important site of physiological interaction as it is a sex steroid responsive organ and a major target of GH action. Estrogen, when administered orally impairs the GH-regulated endocrine and metabolic function of the liver via a first-pass effect. It reduces circulating IGF-I, fat oxidation and protein synthesis, contributing to a loss of lean and a gain of fat mass. These effects occur in normal and in GH-deficient women and are avoided by transdermal administration of physiological doses of estrogen. In contrast, studies in hypopituitary men indicate that testosterone enhances the metabolic effects of GH. Testosterone alone stimulates fat oxidation and protein synthesis, both of which are enhanced by GH. Studies in GH deficiency adults have consistently reported women to be less sensitive to GH than men. In summary, estrogens and androgens exert divergent effects on the action of GH. The results provide an explanation for sexual dimorphism in body composition in adults and the gender-related response to GH replacement in hypopituitary subjects. In the management of hypopituitarism, estrogens should be administered by the parenteral route in women and testosterone be replaced in men to optimize the benefits of GH replacement.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16809927     DOI: 10.1159/000094314

Source DB:  PubMed          Journal:  Front Horm Res        ISSN: 0301-3073            Impact factor:   2.606


  14 in total

1.  IGF-1 levels across the spectrum of normal to elevated in acromegaly: relationship to insulin sensitivity, markers of cardiovascular risk and body composition.

Authors:  Tirissa J Reid; Zhezhen Jin; Wei Shen; Carlos M Reyes-Vidal; Jean Carlos Fernandez; Jeffrey N Bruce; Jane Kostadinov; Kalmon D Post; Pamela U Freda
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

2.  Adipose Tissue Redistribution and Ectopic Lipid Deposition in Active Acromegaly and Effects of Surgical Treatment.

Authors:  Carlos M Reyes-Vidal; Hamed Mojahed; Wei Shen; Zhezhen Jin; Fernando Arias-Mendoza; Jean Carlos Fernandez; Dympna Gallagher; Jeffrey N Bruce; Kalmon D Post; Pamela U Freda
Journal:  J Clin Endocrinol Metab       Date:  2015-06-02       Impact factor: 5.958

3.  Differences in the GH-IGF-I axis in children of different weight and fitness status.

Authors:  Peter A Hosick; Robert G McMurray; A C Hackney; Claudio L Battaglini; Terry P Combs; Joanne S Harrell
Journal:  Growth Horm IGF Res       Date:  2012-03-20       Impact factor: 2.372

4.  Variation of the baseline characteristics and treatment parameters over time: an analysis of 15 years of growth hormone replacement in adults in the German KIMS database.

Authors:  I Kreitschmann-Andermahr; S Siegel; F Francis; M Buchfelder; H J Schneider; P H Kann; H Wallaschofski; M Koltowska-Häggström; G Brabant
Journal:  Pituitary       Date:  2012-12       Impact factor: 4.107

5.  Prediagnosis Circulating Insulin-Like Growth Factors and Pancreatic Cancer Survival.

Authors:  Adetunji T Toriola; Mark Ziegler; Yize Li; Michael Pollak; Rachael Stolzenberg-Solomon
Journal:  Ann Surg Oncol       Date:  2017-07-05       Impact factor: 5.344

Review 6.  Pituitary disease mortality: is it fiction?

Authors:  Eva Marie Erfurth; Peter Siesjö; Thomas Björk-Eriksson
Journal:  Pituitary       Date:  2013-09       Impact factor: 4.107

7.  Assessment of age-related changes in heritability and IGF-1 gene effect on circulating IGF-1 levels.

Authors:  Liran Franco; Frances M K Williams; Svetlana Trofimov; Ida Malkin; Gabriela Surdulescu; Timothy Spector; Gregory Livshits
Journal:  Age (Dordr)       Date:  2014-02-04

Review 8.  Androgen replacement therapy in androgen-deficient women with hypopituitarism.

Authors:  Hong Zang; Susan R Davis
Journal:  Drugs       Date:  2008       Impact factor: 9.546

9.  Influence of neonatal hypothyroidism on hepatic gene expression and lipid metabolism in adulthood.

Authors:  Ruymán Santana-Farré; Mercedes Mirecki-Garrido; Carlos Bocos; Luis A Henríquez-Hernández; Nusrat Kahlon; Emilio Herrera; Gunnar Norstedt; Paolo Parini; Amilcar Flores-Morales; Leandro Fernández-Pérez
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

Review 10.  Normal levels of serum IGF-I: determinants and validity of current reference ranges.

Authors:  G Brabant; H Wallaschofski
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.